Sarcopenia Treatment Market: Insights into Market Trends, Growth Potential, and Competitive Landscape in Aging Population Care

The sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.30 billion in 2023 to $3.52 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to aging population, awareness and diagnosis, lifestyle changes, public health initiatives, regulatory approvals.

The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to personalized medicine, nutritional interventions, digital health platforms, patient education and empowerment, global health initiatives. Major trends in the forecast period include personalized therapies, emergence of novel drug classes, digital health integration, collaborative research initiatives, research and development.

Market Overview -
Sarcopenia treatment refers to medical interventions and lifestyle approaches designed to counteract age-related muscle loss and maintain or improve skeletal muscle mass and function. The treatment is aimed at mitigating age-related muscle loss, improving muscle strength, and enhancing overall physical function and mobility.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp

Surge In Malnutrition Boosts Sarcopenia Treatment Market Growth
The rise in malnutrition is expected to propel the growth of the sarcopenia treatment market going forward. Malnutrition refers to deficiencies, excesses, or imbalances in a person's intake of energy and nutrients, covering both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment helps address the coexisting conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, aiming to improve muscle mass, strength, and overall nutritional status. For instance, in December 2023, according to a report published by the World Health Organization (WHO), a Switzerland-based United Nations (UN) organization, malnutrition remains a significant global health challenge, with an estimated 462 million underweight and 149 million children under 5 suffering from stunting in 2022. Therefore, the rise in malnutrition is driving the growth of the sarcopenia treatment market.

Competitive Landscape -
Major companies operating in the sarcopenia treatment market report are Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill

Biophytis Receives FDA Authorization For Groundbreaking SARA-31 Phase 3 Study
Major companies operating in the sarcopenia treatment market are increasing their focus on development of multiple advance clinical option study to adhere with better treatment option. A clinical study is a systematic investigation conducted on human subjects to evaluate the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, announced the Food and Drug Administration (FDA) authorization to initiate the SARA-31 Phase 3 study in sarcopenia. The study aims to evaluate the efficacy and safety of Sarconeos (BIO101) in the treatment of sarcopenic patients at risk of motor disability. This study demonstrates a significant advancement in technological and pharmaceutical treatment approaches, offering potential efficacy and safety benefits for severe sarcopenic patients. It is the first-ever phase 3 study in sarcopenia and has received FDA authorization. The study will include around 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoint will be the assessment of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

Key Segments -

The sarcopenia treatment market covered in this report is segmented -

1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types
2) By Type: Primary Sarcopenia, Secondary Sarcopenia
3) By Route Of Administration: Oral, Parenteral, Enteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.